Abstract-Left ventricular hypertrophy and systolic dysfunction predict mortality in patients with end-stage renal disease.
C ardiovascular disease is the leading cause of death in patients with end-stage renal disease (ESRD) and is partly attributed to the high prevalence of accelerated atherosclerosis and left ventricular (LV) hypertrophy. Of patients starting long-term dialysis therapy, LV hypertrophy was already present in nearly three quarters and was frequently complicated with LV dilatation and systolic dysfunction. 1 Furthermore, progressive worsening of cardiac dilatation with compensatory hypertrophy continued with time on dialysis. 2 In patients with ESRD, both LV hypertrophy and systolic dysfunction have been shown to be important predictors of outcome, and there is a high prevalence of circulatory congestion. 1, [3] [4] [5] Furthermore, patients with a history of heart failure at the initiation of dialysis were noted to have higher mortality. 6 Thus, the ability to assess LV filling pressure noninvasively using echocardiography may serve as an important clinical tool and add important value for prognostication in this group of patients. Recently, the ratio of early transmitral flow velocity (E) to early diastolic mitral annular velocity (Em) (E/Em ratio) assessed using tissue Doppler imaging may be more accurate than other methods for estimating LV filling pressure 7 and has been shown to be an excellent predictor of diastolic filling in different subsets of patients. 8 -11 Therefore, the objective of this study was to investigate whether the estimation of the E/Em ratio using tissue Doppler imaging adds significant long-term prognostic value beyond that of standard clinical, biochemical, dialysis, and echocardiographic parameters in patients with ESRD.
Methods

Study Design and Subjects
This was a 4-year prospective study performed in 220 stable patients with ESRD receiving maintenance peritoneal dialysis (PD) at a regional dialysis center in Hong Kong. The study protocol complies with the Declaration of Helsinki and had full approval from the local clinical research ethics committee. All of the patients provided informed consent before study entry.
Patients were considered eligible for study inclusion if they had received continuous PD treatment for Ն3 months. Exclusion criteria included severe valvular stenosis or regurgitation, hypertrophic cardiomyopathy, underlying malignancy, chronic liver disease, systemic lupus erythematosus, chronic rheumatic heart disease, congenital heart disease, patients who refusal to give consent, or incomplete data. Fifty patients were excluded by these criteria, representing 18.5% of the total PD population. All of the patients were continuously dialyzed using conventional lactate-buffered glucose-based PD solutions. In those who developed acute coronary syndrome, acute heart failure, peritonitis, exit site infections, or any other infective complications, assessments were deferred for Ն1 month after complete resolution of the complication.
Clinical and Demographic Data
Known clinical atherosclerotic vascular disease was defined as the presence of coronary artery disease (indicated by history of angina, previous myocardial infarction with or without history of coronary artery bypass surgery, or percutaneous intervention), cerebrovascular disease (indicated by history of cerebrovascular event or transient ischemic attack), and peripheral vascular disease (indicated by the presence of intermittent claudication or resting leg pain, together with clinical signs of peripheral vascular disease with or without a history of amputation or revascularization). With a mercury sphygmomanometer, systolic and diastolic blood pressures were measured once on every follow-up visit after the patient was rested for 15 minutes on either arm at 8-week intervals for 12 months preceding study entry and were then averaged to give the final systolic and diastolic blood pressure.
Echocardiography and Tissue Doppler Imaging
Echocardiography was performed at study entry using a GEVingMed System 5 echocardiographic machine (GE-VingMed Sound AB) with a 3.3-mHz multiphase array probe in subjects lying in the left decubitus position by a single experienced cardiologist blinded to all of the clinical details of patients. The echocardiographic techniques and calculation of different cardiac dimensions and volumes were performed according to the guidelines of the American Society of Echocardiography. 12 LV ejection fraction was obtained using a modified biplane Simpson's method from apical 2-and 4-chamber views. 13 Midwall fractional shortening (mwFS) was calculated according to the formula as described by Mayet et al. 14 The LV mass was calculated using the modified American Society of Echocardiography cube formula proposed by Devereux et al 15 and indexed by body surface area. LV hypertrophy was defined as LV mass indexed by body surface area Ͼ131 g/m 2 in men and Ͼ100 g/m 2 in women. 16, 17 Mitral inflow velocities were recorded using pulsed wave Doppler with the sample volume placed at the tip of the mitral valve tips from the apical 4-chamber view. From the mitral valve inflow velocity curve, the following measurements were made: peak E-wave velocity and its deceleration time, peak A-wave velocity, and the isovolumetric relaxation time were measured from the aortic valve closure to the mitral valve opening. 18 A composite of these conventional Doppler measurements was used to define diastolic dysfunction. 19, 20 Abnormal diastolic function was further categorized into an abnormal relaxation filling pattern, restrictive filling pattern, and pseudonormal filling pattern. 21 Myocardial velocities were recorded using the tissue Doppler technique, as described previously. 9, 22 Color-coded tissue Doppler images were acquired over a predetermined 2 consecutive cardiac cycles for each of the 4 mitral segments and were transferred to a workstation composed of a personal computer of which the software package provides customized image visualization, processing, and analysis (EchoPac, GE-VingMed). The sample volume was placed in the mitral annulus of septal and lateral myocardial segments from the 4-chamber view and inferior and anterior myocardial segments from the 2-chamber views. Mean velocities during systole, early diastole, and late diastole were measured. The final value represented the average of 4 sites.
Biochemical Analysis
EDTA and heparinized blood samples were collected at baseline for measurement of high-sensitivity C-reactive protein, serum albumin, blood hemoglobin, urea, creatinine, calcium, phosphorus, and intact parathyroid hormone. High-sensitivity C-reactive protein and albumin in heparin plasma were measured, respectively, using the Tina-quant C-reactive protein latex ultrasensitive assay and the bromocresol purple method on the Roche analyzer. Serum intact parathyroid hormone was measured by the IMMULITE 1000 Analyzer (Diagnostic Products Corporation).
Assessment of Residual Renal Function and Dialysis Indices
Twenty-four-hour urine and dialysate was collected for the measurement of residual glomerular filtration rate, total weekly urea, and creatinine clearance using standard methods. 23, 24 
Outcome Measures
All of the patients were prospectively followed Յ4 years from the day of baseline assessment or until death. The cause of death was determined by the attending physicians, who had no knowledge of the tissue Doppler imaging results. This information was identified from the computerized clinical management system of the Hong Kong Hospital Authority and the Renal Registry Database that keeps detailed records of all hospitalization episodes and causes of death. In case of death out of the hospital, family members were interviewed by telephone to ascertain the circumstances surrounding death. No patient was lost to follow-up.
The outcome measures evaluated were death from all causes and cardiovascular death. Cardiovascular death included death associated with a definite myocardial ischemic event, heart failure, cerebrovascular event, arrhythmia, and peripheral vascular accident, all of which were defined according to standard clinical criteria, as well as sudden cardiac death, which was defined as unexpected natural death within 1 hour from the symptom onset and without any previous condition that would appear fatal. 25, 26 
Statistical Analysis
Continuous data were expressed as meansϮSDs or median (interquartile range) and categorical data as percentages. Comparisons between groups were done by the unpaired t test for mean data, Mann-Whitney U test for median data, or 2 test for categorical data. Comparisons of baseline characteristics among patients who remained alive on dialysis at the end of 4 years and those who died from cardiovascular and noncardiovascular causes were done by the 1-way ANOVA, Kruskal-Wallis test, or 2 test, where appropriate. Multivariate logistic regression of the E/Em ratio Ն15 was performed by considering factors with PϽ0.25 in the univariate analysis.
Cumulative survival curves were generated by the Kaplan-Meier method, and between-group survival was compared by the log-rank test. In this analysis, patients who underwent kidney transplant or were transferred to hemodialysis during follow-up were censored at the time of transfer to alternative renal replacement therapy. If a patient died within 3 months of transfer to hemodialysis, then he or she was not censored, because the early mortality was considered to reflect the health status during the period of failing PD treatment. We used a Cox proportional hazards model to estimate the hazard ratios of all-cause mortality and cardiovascular death in relation to the E/Em ratio and other variables. We checked that all of the variables considered in the regression analysis met the assumption of proportional hazards. Variables that showed significant difference between patients who remained alive on dialysis and those who died from cardiovascular or noncardiovascular causes were considered in the multivariable Cox regression analysis. To have adequate confounder control, important covariates, such as gender, duration of dialysis, and presence of hypertension, were retained in all of the models regardless of their statistical significance.
The incremental value of E/Em ratio over other clinical, demographic, biochemical, dialysis, and conventional echocardiographic parameters was assessed by a modified stepwise procedure in 4 modeling steps. The first model consisted of baseline clinical, demographic, biochemical, and dialysis risk factors. The second model consisted of adding LV mass index. The third step consisted of adding mwFS. The final step was entering either E/Em ratio or conventional Doppler-defined diastolic dysfunction into the model. A significant improvement in model prediction was based on the Ϫ2 log likelihood ratio statistic, which follows a 2 distribution, and the P value was based on the incremental value compared with the previous model. A risk score for each subject based on each model was calculated by multiplying the coefficient estimate for each variable from the fully adjusted Cox model by the value of the variable for each patient and then adding these figures for each patient. This risk score was then used to calculate the predictive value of each model using the receiver-operator characteristics curve analysis. Statistical analysis was performed using SPSS version 14.0 (SPSS, Inc).
Results
The baseline characteristics of the study population are shown in Table 1 . Of the 222 patients, 2 patients (0.9%) had E/Em ratios Ͻ8, 81 patients (36.8%) had E/Em ratios of 8 to 15, and 137 patients (62.3%) had E/Em ratios Ͼ15 (which identifies an abnormally elevated LV filling pressure). 7 Because there were only 2 patients with E/Em ratios Ͻ8, the group with E/Em ratios Ͻ8 and 8 to 15 were merged together for analysis. The baseline characteristics of patients with E/Em ratios Ͼ15 versus those with E/Em ratios Յ15 are compared in Table 1 . The differences in echocardiographic parameters between the 2 groups of patients are presented in Table 2 . Using multiple logistic regression analysis, an elevated E/Em ratio Ͼ15 showed the strongest correlation with LV volume index, followed by residual glomular filtration rate, age, LV ejection fraction, and diabetes (Table 3) . During the 48-month follow-up, 84 patients had died, 27 patients underwent kidney transplantation, and 24 patients were switched to long-term hemodialysis. Fifty-three deaths (63%) were of cardiovascular causes, and 31 deaths were because of noncardiovascular causes. The cardiovascular deaths included ischemic heart disease/acute myocardial infarction in 7 patients, cerebrovascular events in 14 patients, sudden cardiac death in 22 patients, heart failure in 4 patients, peripheral vascular disease in 5 patients, and arrhythmia in 1 patient. The noncardiovascular deaths included peritonitis in 12 patients, other infective complications in 13 patients, malignancy in 1 patient, and termination of dialysis in 5 patients. The baseline characteristics of patients who remained alive on PD and patients who died from cardiovascular and noncardiovascular causes are presented in Figure  S1 (please see http://hyper.ahajournals.org). The baseline E/Em ratio was the highest among patients who died from cardiovascular causes. Figures 1A and 1B show the Kaplan-Meier estimates of overall survival and cardiovascular event-free survival probability for patients stratified by tertiles of the E/Em ratio. On univariate analysis, the hazard ratios associated with E/Em ratio in relation to all-cause mortality and cardiovascular death were 1.051 (95% CI: 1.033 to 1.069; PϽ0.001) and EDD indicates end-diastolic diameter; ESD, end-systolic diameter; IVSd, interventricular septal thickness at end-diastole; IVSs, interventricular septal thickness at end-systole; PWd, posterior wall thickness at end-diastole; PWs, posterior wall thickness at end-systole; LADs, left atrial diameter at end-systole; EF, ejection fraction; FS, fractional shortening; E, early diastolic transmitral inflow velocity; A, late diastolic transmitral flow velocity, DT, deceleration time; IVRT, isovolumetric relaxation time; E/A, ratio of early to late transmitral flow velocity; Sm, systolic mitral annual velocity; Em, mitral annular diastolic velocity; Am, late diastolic mitral annular velocity. Percentage may not add up to 100 because of rounding off of decimal places.
1.055 (95% CI: 1.034 to 1.076; PϽ0.001), respectively. In the multivariable Cox regression analysis, the E/Em ratio was associated with an increased risk of all-cause mortality (adjusted hazard ratio: 1.027; 95% CI: 1.003 to 1.051; Pϭ0.026; Figure  S2 ) and cardiovascular death (adjusted hazard ratio: 1.033; 95% CI: 1.002 to 1.065; Pϭ0.035; Figure S3 ).
The predictive value for all-cause mortality and cardiovascular death was the highest in the model, including demographic, clinical, biochemical, and dialysis risk factors, as well as LV mass index, mwFS, and E/Em ratio (model 4B; Table 4 ). Including conventional Doppler-defined diastolic dysfunction did not increase the predictive value for all-cause mortality and cardiovascular death (model 4A; Table 4 ).
The incremental value of the E/Em ratio and conventional Doppler-defined diastolic dysfunction in outcome prediction is shown in Figure 2A and 2B. E/Em ratio improved the prognostic value for all-cause mortality (Pϭ0.035; model 4B, Figure 2A ) and cardiovascular death (Pϭ0.035; model 4B, Figure 2B ) in a model including clinical, demographic, biochemical, and dialysis risk factors, as well as LV mass index and mwFS. However, conventional Doppler-defined diastolic dysfunction had no significant incremental value in predicting all cause mortality (model 4A; Figure 2A ) and cardiovascular death (model 4A; Figure 2B ).
Discussion
In this study, we showed that Ͼ60% of our patients with ESRD had elevated LV filling pressure. More importantly, we demonstrated that combining the transmitral flow velocity with annular velocity (E/Em ratio) provides independent and additional prognostic value for long-term (4 years) mortality and cardiovascular death in patients with ESRD above and beyond that of clinical, biochemical, dialysis, and echocardiographic parameters, including LV mass and systolic function. Studies have shown that E/Em ratio is the single best Doppler predictor of elevated LV filling pressure 7 and a powerful independent predictor of all-cause mortality in a general cardiac population in those with LV systolic dysfunc- Follow-up months Follow-up months Figure 1 . A, Kaplan-Meier estimates of overall survival probability of patients with ratio of E/Em stratified by tertiles. Lower tertile: E/Em ratio Յ14.43; middle tertile: E/Em ratio Ͼ14.43 to 21.73; upper tertile: E/Em ratio Ͼ21.73. Log-rank test showed significant difference in overall survival probability between lower and middle tertiles (Pϭ0.037), lower and upper tertiles (PϽ0.0001), and middle and upper tertiles (Pϭ0.026). B, Kaplan-Meier estimates of cardiovascular event-free survival probability of patients with ratio E/Em stratified by tertiles. Lower tertile: E/Em ratio Յ14.43; middle tertile: E/Em ratio Ͼ14.43 to 21.73; upper tertile: E/Em ratio Ͼ21.73. Log-rank test showed significant difference in overall survival probability between lower and upper tertiles (PϽ0.0001) and between middle and upper tertiles (Pϭ0.003) but not between lower and middle tertiles (Pϭ0.56). Figure 2 . A, Incremental value of ratio of E/Em in predicting long-term mortality. The addition of LV mass index and E/Em ratio but not midwall fractional shortening or conventional Doppler-defined diastolic dysfunction significantly improved the predictive value of a model, including clinical, demographic, biochemical, and dialysis risk factors: 2 ϭ83.53 with 11 degrees of freedom for demographic (age and gender), clinical (diabetes mellitus, background atherosclerotic vascular disease, hypertension, and duration of dialysis), biochemical (hemoglobin, C-reactive protein, and serum albumin), and dialysis (residual glomerular filtration rate) risk factors; 2 ϭ94.34 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index (Pϭ0.002); 2 ϭ95.87 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index plus midwall fractional shortening (Pϭ0.21); 2 ϭ95.97 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index plus ejection fraction plus conventional Doppler-defined diastolic dysfunction (Pϭ0.25); 2 ϭ98.04 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index plus midwall fractional shortening plus E/Em ratio (Pϭ0.035). B, Incremental value of ratio of E/Em in predicting long-term cardiovascular death. The addition of LV mass index and E/Em ratio but not midwall fractional shortening or conventional Doppler-defined diastolic dysfunction significantly improved the predictive value of a model including clinical (diabetes mellitus, background atherosclerotic vascular disease, hypertension, and duration of dialysis), demographic (age and gender), biochemical (hemoglobin, C-reactive protein, and albumin), and dialysis (residual glomerular filtration rate) risk factors: 2 ϭ62.95 with 11 degrees of freedom for clinical, demographic, biochemical, and dialysis risk factors; 2 ϭ66.51 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index (Pϭ0.023); 2 ϭ67.68 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index plus midwall fractional shortening (Pϭ0.13); 2 ϭ67.78 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index plus ejection fraction plus conventional Doppler-defined diastolic dysfunction (Pϭ0.52); 2 ϭ69.82 with 1 degree of freedom for clinical, demographic, biochemical, and dialysis risk factors plus LV mass index plus midwall fractional shortening plus E/Em ratio (Pϭ0.035). tion and after acute myocardial infarction [27] [28] [29] and correlates better with pulmonary capillary wedge pressure than brain natriuretic peptide. 30 More recently, a study in the ESRD population showed that an E/Em ratio of Ն15 has a sensitivity of 82% and a specificity of 88% in predicting LV end-diastolic pressure Ͼ15 mm Hg, 31 suggesting that an E/Em ratio Ͼ15 is a reliable marker of increased LV filling pressure in this population. Taken together with our current data, this suggests that the additional prognostic value contributed by the E/Em ratio beyond that of LV mass and mwFS is most likely explained because it is reflecting an increased LV filling pressure in the patients with ESRD. Notably, the E/Em ratio appeared to be a more significant predictor of long-term mortality and cardiovascular death compared with mwFS. A higher E/Em ratio, indicating a higher LV diastolic filling pressure, was associated with greater LV hypertrophy and dilatation and more systolic dysfunction. However, only the E/Em ratio retained independent significance in the multivariable Cox regression model for cardiovascular death. We stratified patients by the E/Em ratio of 15. As shown in the general population, this is the optimum cutoff value above which patients are considered to have an elevated LV filling pressure, as determined by measuring the mean LV end-diastolic pressure at cardiac catheterization and also as currently recommended by the European Society of Cardiology. 7, 20 It is worth noting that only 2 patients in our cohort had E/Em ratios Ͻ8. The finding that an E/Em ratio Ͼ15 showed the strongest correlation with LV volume index provides additional evidence that increased LV filling pressure of patients with ESRD may be partly attributed to extracellular volume expansion. Our observation is in keeping with an earlier study suggesting that volume loads and ventricular distensibility modifications are the primary factors that influence LV filling pressure in uremic patients. 32 Loss of residual renal function was second to LV volume index as the most significant factor associated with an increased E/Em ratio in our patients. This well accords with our previous data showing an important link between residual renal function and cardiac hypertrophy 33 in PD patients and suggests that an increased LV filling pressure is reflecting the degree of LV hypertrophy.
In addition, an E/Em ratio Ͼ15 appeared to identify the sickest patients with ESRD as evidenced by the greater prevalence of diabetes, atherosclerotic vascular disease and heart failure, higher systolic blood pressure, greater inflammation, more anemia and hypoalbuminemia, and lower residual renal function compared with those with E/Em Յ15. This is consistent with studies showing that LV hypertrophy, reduced aortic distensibility, diabetes, and coronary artery disease may all contribute to an increased LV filling pressure in ESRD. 28, 34, 35 Furthermore, a higher E/Em ratio was associated with a worse echocardiographic profile. Indeed, systolic dysfunction emerged as one of the significant factors associated with an elevated E/Em ratio. Thus, the E/Em ratio should not be considered only as a measure of volume status but rather as surrogate marker of LV filling pressure, which may be elevated from multiple causes, including extracellular volume expansion.
Our study has several limitations. First, only prevalent dialysis patients were included, which may introduce survival bias. Second, all of the parameters were measured at a single time point and did not reflect changes over time. Third, invasive measurement of LV filling pressure was not performed simultaneously. However, as shown by other studies, the E/Em ratio correlates well with LV filling pressure. 7, 9, 30 Fourth, volume status was not directly assessed in our patients, and it is not known whether an E/Em ratio may vary according to the volume status. It was reported previously that volume reduction affects mitral inflow velocities in hemodialysis patients. 36 Mitral annular velocity was also volume dependent, yet, to a lesser extent than mitral inflow velocities. 22, 37, 38 However, there is currently no similar data in PD patients.
Perspectives
This study demonstrates the incremental value of measuring the ratio of early mitral inflow velocity to peak mitral annulus velocity (E/Em ratio), an estimate of LV filling pressure, over other standard clinical, biochemical, and dialysis risk factors and conventional echocardiographic and Doppler-derived measures for prognostication in patients with ESRD. Our data suggest that LV filling pressure should be assessed during echocardiographic examination of patients with ESRD for additional prognostication and cardiovascular risk stratification. GFR indicates glomerular filtration rate; E/Em, ratio of mitral velocity to early diastolic velocity of the mitral annulus; CI, confidence intervals.
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